News �鶹��ý from BioMed Valley Discoveries

Biomed Valley Discoveries Announces Poster Presentations on Ulixertinib (BVD-523) at the AACR Annual Meeting 2022

BioMed Valley Discoveries — Tue, 22 Mar 2022 10:30:00 EST

BioMed Valley Discoveries (BVD) announced today they will present four posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

BioMed Valley Discoveries' ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II trial in collaboration with Cmed and Strata Oncology

BioMed Valley Discoveries — Tue, 28 Jul 2020 12:15:05 EST

BioMed Valley Discoveries (BVD), a clinical stage biotechnology company, announces the receipt of Fast Track designation from the US Food and Drug Administration (FDA) for investigation of the ERK inhibitor ulixertinib (BVD-523) as a treatment for patients with non-colorectal, solid tumors that harbor BRAF mutations G469A/V, L485W, or L597Q. BVD has launched a Phase II multi-center study of ulixertinib for patients with advanced malignancies harboring these atypical (non-V600) BRAF alterations or a MEK alteration.

X marks the spot: recombination in structurally distinct chromosomes

BioMed Valley Discoveries — Wed, 16 Oct 2019 10:05:45 EST

A recent study from the laboratory of Stowers Investigator Scott Hawley, PhD, has revealed more details about how the synaptonemal complex performs its job, including some surprising subtleties in function.

Bacterial Biosurgery Shows Promise for Reducing the Size of Inoperable Tumors

BioMed Valley Discoveries — Wed, 13 Aug 2014 14:00:00 EST

Deep within most tumors lie areas that remain untouched by chemotherapy and radiation. These troublesome spots lack the blood and oxygen needed for traditional therapies to work, but provide the perfect target for a new cancer treatment using bacteria that thrive in oxygen-poor conditions. Now, researchers have shown that injections of a weakened version of one such anaerobic bacteria -- the microbe Clostridium novyi -- can shrink tumors in rats, pet dogs, and a human patient.